Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Scotti, A; Coisne, A; Taramasso, M; Granada, JF; Ludwig, S; Rodés-Cabau, J; Lurz, P; Hausleiter, J; Fam, N; Kodali, SK; Rosiene, J; Feinberg, A; Pozzoli, A; Alessandrini, H; Biasco, L; Brochet, E; Denti, P; Estevez-Loureiro, R; Frerker, C; Ho, EC; Monivas, V; Nickenig, G; Praz, F; Puri, R; Sievert, H; Tang, GHL; Andreas, M; Von Bardeleben, RS; Rommel, KP; Muntané-Carol, G; Gavazzoni, M; Braun, D; Koell, B; Kalbacher, D; Connelly, KA; Juliard, JM; Harr, C; Pedrazzini, G; Russo, G; Philippon, F; Schofer, J; Thiele, H; Unterhuber, M; Himbert, D; Alcázar, MU; Wild, MG; Windecker, S; Jorde, U; Maisano, F; Leon, MB; Hahn, RT; Latib, A.
Sex-related characteristics and short-term outcomes of patients undergoing transcatheter tricuspid valve intervention for tricuspid regurgitation
EUR HEART J. 2023; 44(10): 822-832. Doi: 10.1093/eurheartj/ehac735
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Andreas Martin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Aims The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone. Methods and results The Transcatheter Tricuspid Valve Therapies (TriValve) registry collected data on patients with significant TR from 24 centres who underwent TTVI from 2016 to 2021. A control cohort was formed by medically managed patients with >= severe isolated TR diagnosed in 2015-18. The primary endpoint was freedom from all-cause mortality. Secondary endpoints were heart failure (HF) hospitalization, New York Heart Association (NYHA) functional status, and TR severity. One-year outcomes were assessed for the TriValve cohort and compared with the control cohort with the inverse probability of treatment weighting (IPTW). A total of 556 and 2072 patients were included from the TriValve and control groups, respectively. After TTVI, there was no difference between women and men in 1-year freedom from all-cause mortality 80.9% vs. 77.9%, P = 0.56, nor in HF hospitalization (P = 0.36), NYHA Functional Classes III and IV (P = 0.17), and TR severity >2+ at last follow-up (P = 0.42). Multivariable Cox-regression weighted by IPTW showed improved 1-year survival after TTVI compared with medical therapy alone in both women (adjusted hazard ratio 0.45, 95% confidence interval 0.23-0.83, P = 0.01) and men (adjusted hazard ratio 0.42, 95% confidence interval 0.18-0.89, P = 0.03). Conclusion After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
Find related publications in this database (Keywords): Tricuspid regurgitation; Sex; Transcatheter tricuspid valve intervention